CINC - Hypertension drug developer CinCor sees stock rally 15%

CinCor (CINC) stock rallied 15% on Monday, with the stock having risen 29% over the last five sessions.  Shares of CINC opened at $21.99 and climbed steadily during morning trading. The stock recently changed hands at $24.99, up 15%, at approximately 1:40 p.m. CINC held its initial public offering on Jan. 7, offering 12.1M shares priced at $16 per share to raise gross proceeds of $193.6M. On March 18, the stock was added to the Russell 2000 and 3000 Indexes. The company has been focused on developing its lead drug candidate, CIN-107, as a treatment for hypertension and other cardio-renal diseases. The product is in Phase 3 testing for treatment-resistant hypertension, according to its website. For more on CINC, check out SA contributor Avisol Capital Partners’ “CinCor: 2022 Data Catalysts Will De-risk the Stock”.

For further details see:

Hypertension drug developer CinCor sees stock rally 15%